Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)

Unity Biotechnology, Inc. (NASDAQ:UBX) – HC Wainwright issued their Q1 2024 earnings estimates for shares of Unity Biotechnology in a report released on Tuesday, April 16th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.57) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.

Unity Biotechnology Trading Down 1.0 %

NASDAQ:UBX opened at $1.51 on Wednesday. The firm has a market capitalization of $25.25 million, a price-to-earnings ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a 1-year low of $1.50 and a 1-year high of $3.82. The business’s fifty day moving average price is $1.66 and its 200 day moving average price is $1.78.

Institutional Trading of Unity Biotechnology

A number of institutional investors have recently added to or reduced their stakes in UBX. Vanguard Group Inc. boosted its stake in shares of Unity Biotechnology by 246.2% during the 3rd quarter. Vanguard Group Inc. now owns 4,437,259 shares of the company’s stock worth $1,753,000 after acquiring an additional 3,155,586 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Unity Biotechnology by 65.2% in the 3rd quarter. Renaissance Technologies LLC now owns 1,582,369 shares of the company’s stock worth $625,000 after purchasing an additional 624,651 shares during the last quarter. Armistice Capital LLC bought a new stake in Unity Biotechnology during the fourth quarter worth approximately $1,328,000. Acadian Asset Management LLC grew its holdings in Unity Biotechnology by 39.8% during the first quarter. Acadian Asset Management LLC now owns 389,893 shares of the company’s stock valued at $435,000 after purchasing an additional 111,097 shares during the last quarter. Finally, State Street Corp raised its position in shares of Unity Biotechnology by 32.4% in the third quarter. State Street Corp now owns 172,640 shares of the company’s stock valued at $68,000 after purchasing an additional 42,200 shares during the period. 29.49% of the stock is currently owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.